Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease.
about
Interleukin-10: new perspectives on an old cytokineNanomedicine and drug delivery strategies for treatment of inflammatory bowel diseaseRecent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel diseaseThe relationship between the immune system and oral manifestations of inflammatory bowel disease: a reviewTranslational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory DiseasesStem cells as potential therapeutic targets for inflammatory bowel disease.Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel diseaseMucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis.Non-condensing polymeric nanoparticles for targeted gene and siRNA deliveryDevelopment of a pH-responsive particulate drug delivery vehicle for localized biologic therapy in inflammatory bowel diseaseEvaluation of In Vivo Transfection Efficiency of Eudragit Coated Nanoparticles of Chitosan-DNA: A pH-sensitive System Prepared for Oral DNA Delivery.Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease.Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells.Do we really understand what the immunological disturbances in inflammatory bowel disease mean?Colonic treatments and targets: issues and opportunities.Regulatory T cells and inhibitory cytokines in autoimmunity.Inflamed gut mucosa: downstream of interleukin-10.Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease.Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.New therapeutic avenues in ulcerative colitis: thinking out of the box.Nanotechnology in the treatment of inflammatory bowel diseases.Targeted delivery systems for biological therapies of inflammatory diseases.Hydrodynamic IL10 Gene Transfer in Human Colon: Results from an "EX VIVO" Study with Potential Clinical Application in Crohn's Disease.Delivery strategies to control inflammatory response: Modulating M1-M2 polarization in tissue engineering applications.Bioengineered Colorectal Cancer Drugs: Orally Delivered Anti-Inflammatory Agents.Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa.Oral nucleic acid therapy using multicompartmental delivery systems.Multi-compartmental nanoparticles-in-emulsion formulation for macrophage-specific anti-inflammatory gene delivery.Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis.Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.
P2860
Q24653771-A21A5BD0-30C4-4A01-A83C-1DA7AD10D7B1Q26777400-01CFF26A-25A3-4DC9-A466-968101315705Q28073219-BF85E6A9-3CE5-40BF-A4B3-8645C007CE31Q28078219-F10DC264-4964-4058-8003-140B1EBB48A7Q28548580-0A2F2B86-5BEB-4C33-AD0D-5648E024D2DFQ33975300-03FC9248-2D05-4492-BAC1-FD99DCA891CFQ34030833-CBC6D136-267F-423C-B5D4-CEDDBA0CDAFEQ34553476-C065D970-1090-4288-AE26-54CD9E17FD50Q35142393-C105494F-6007-4DC2-83C4-91B6BFEA8B92Q35190149-946A9319-DF54-47F7-BF2A-4C30A2EF457EQ35228674-2C90426D-D37E-4745-AFB7-D7A1DEC71817Q35645058-CD8C7AC9-5986-4D1F-B90A-CD0ABFF8ED08Q35877982-A626E8A8-43ED-4861-B8E7-7C873527FF01Q36002746-65672448-074E-4A3E-8BD1-5D5874ABBEEBQ37065810-8BADD10B-AF00-4690-8A63-B98CA66F017EQ37385966-39B3EB65-3698-4F02-ADE6-465E45E50B83Q37530912-6446C979-C1B9-4ACA-9F28-C9684E67E057Q37621070-BB710BD9-4CFA-4640-9F1C-A2092658F2A0Q37883443-DADA3F83-1EC6-4F71-9067-D014713DEDD6Q38034469-ED53D764-9077-437D-89CB-DE1B90177066Q38049367-CB141171-9434-44E7-AC8A-075F1EEC71CBQ38110619-3A6089C7-0427-4E66-B0CC-531471DD66A2Q38150670-859719B5-6FD6-44F1-A598-FAB006FBA153Q38200842-6202189E-99AA-4CAD-A30B-9543774EB212Q38264691-78C4B869-A433-459F-B6DB-8BD48BFBF158Q38678884-5873E790-F042-454D-AA19-19DB01CE1160Q38700498-7E491643-794E-4D70-B35F-2BD48B507B5FQ38879552-6D159412-C4C1-4C92-B751-C8DDAC39B223Q39170844-22947518-7C4E-4281-88B2-9E6182AE79EDQ39330117-4ECA80AF-21E7-4C69-A1F7-605A158040D4Q39405505-46E89C8C-EC9B-44BD-871D-E2E9593C3FDCQ39683389-1A922450-1C35-4268-9A99-451CE40DF1A3Q43202907-5B0F0609-26D2-447E-94E5-CE975B27F03C
P2860
Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Oral IL-10 gene delivery in a ...... in inflammatory bowel disease.
@en
Oral IL-10 gene delivery in a ...... in inflammatory bowel disease.
@nl
type
label
Oral IL-10 gene delivery in a ...... in inflammatory bowel disease.
@en
Oral IL-10 gene delivery in a ...... in inflammatory bowel disease.
@nl
prefLabel
Oral IL-10 gene delivery in a ...... in inflammatory bowel disease.
@en
Oral IL-10 gene delivery in a ...... in inflammatory bowel disease.
@nl
P2860
P356
P1433
P1476
Oral IL-10 gene delivery in a ...... in inflammatory bowel disease.
@en
P2093
M D Bhavsar
P2860
P2888
P304
P356
10.1038/GT.2008.67
P577
2008-04-17T00:00:00Z
P5875
P6179
1011695641